Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis

Purpose To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem). Methods Between 2011 and 2017, we identified the Bev–Gem and Gem PROC groups. The regimen includ...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2018-05, Vol.81 (5), p.809-814
Main Authors: Takasaki, Kazuki, Miyamoto, Morikazu, Takano, Masashi, Soyama, Hiroaki, Aoyama, Tadashi, Matsuura, Hiroko, Kato, Kento, Sakamoto, Takahiro, Kuwahara, Mika, Iwahashi, Hideki, Ishibashi, Hiroki, Yoshikawa, Tomoyuki, Furuya, Kenichi
Format: Article
Language:English
Subjects:
Bevacizumab
Cancer
Cancer Research
Gemcitabine
Identification methods
Immunotherapy
Medicine
Medicine & Public Health
Monoclonal antibodies
Oncology
Original Article
Ovarian cancer
Patients
Pharmacology/Toxicology
Platinum
Remission
Side effects
Survival
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem). Methods Between 2011 and 2017, we identified the Bev–Gem and Gem PROC groups. The regimen included 1000 mg/m 2 of Gem on days 1, 8, and 15, and 15 mg/m 2 of Bev on day 1, every 4 weeks. Progression-free survival (PFS) and overall survival (OS) were calculated from the date of the administration of Bev–Gem or Gem until disease progression or death. Results The Bev–Gem and Gem groups included 18 and 29 patients, respectively. More patients had advanced stage disease in the Bev–Gem group ( p  = 0.048); no other characteristics differed between the groups. The response rates [ratio of complete remission (CR) to partial remission (PR)] of Bev–Gem and Gem were 38.9 and 3.4%, respectively ( p  
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-018-3552-5